New study tracks PNH patients in china to uncover disease patterns

NCT ID NCT06154512

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study followed 724 people in China with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers aimed to better understand how the disease progresses and how patients respond to different treatments, including the newly available drug eculizumab. The study collected data on symptoms, complications like blood clots and kidney failure, and treatment patterns to improve future care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could provide a clearer picture of how PNH progresses in Chinese patients and how well current treatments work in the real world.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may not apply to other populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemoglobinuria, Paroxysmal paroxysmal nocturnal hemoglobinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Contacts and locations

Show contact details

Locations

Research Site

Hefei, Anhui, 230002, China
Research Site

Beijing, Beijing Municipality, 100000, China
Research Site

Beijing, Beijing Municipality, 100044, China
Research Site

Guangzhou, Guangdong, 510080, China
Research Site

Guangzhou, Guangdong, 510180, China
Research Site

Guangzhou, Guangdong, 510515, China
Research Site

Nanning, Guangxi, 530021, China
Research Site

Guiyang, Guizhou, 550004, China
Research Site

Shijiazhuang, Hebei, 050000, China
Research Site

Harbin, Heilongjiang, 150001, China
Research Site

Zhengzhou, Henan, 450003, China
Research Site

Zhengzhou, Henan, 450052, China
Research Site

Zhengzhou, Henan, 463599, China
Research Site

Wuhan, Hubei, 430000, China
Research Site

Wuhan, Hubei, 430030, China
Research Site

Changsha, Hunan, 410005, China
Research Site

Changsha, Hunan, 410008, China
Research Site

Nanjing, Jiangsu, 210029, China
Research Site

Nantong, Jiangsu, 226001, China
Research Site

Xuzhou, Jiangsu, 221002, China
Research Site

Nanchang, Jiangxi, 330006, China
Research Site

Nanchang, Jiangxi, 330008, China
Research Site

Changchun, Jilin, 130021, China
Research Site

Shenyang, Liaoning, 110001, China
Research Site

Jinan, Shandong, 250000, China
Research Site

Qingdao, Shandong, 266000, China
Research Site

Zibo, Shandong, 255090, China
Research Site

Linyi, Shangdong, 276034, China
Research Site

Shanghai, Shanghai Municipality, 200040, China
Research Site

Shanghai, Shanghai Municipality, 200336, China
Research Site

Taiyuan, Shanxi, 030000, China
Research Site

Xi’an, Shanxi, 710061, China
Research Site

Xi’an, Shanxi, 710068, China
Research Site

Chengdu, Sichuan, 610041, China
Research Site

Chengdu, Sichuan, 610072, China
Research Site

Tianjin, Tianjin Municipality, 300020, China
Research Site

Tianjin, Tianjin Municipality, 300052, China
Research Site

Tianjin, Tianjin Municipality, 300190, China
Research Site

Kunming, Yunnan, 650034, China
Research Site

Hangzhou, China